Therefore, the absence of mortality benefit should be interpreted in the context of these factors and does not negate the potential long-term advantages of GLP-1 RA therapy, consistent with the ongoing morbidity and mortality experienced by adult CHD patients many years after surgical correction of their congenital heart disease [20]. The gene discussed is GLP1R; the disease is congenital heart disease.